Get the Stockscreener App
90.71
2.92%
-2.73
Pre-market:
90.56
-0.15
-0.17%
Dianthus Therapeutics Inc stock is traded at $90.71, with a volume of 726.17K.
It is down -2.92% in the last 24 hours and down -17.59% over the past month.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
See More
Previous Close:
$93.44
Open:
$93.75
24h Volume:
726.17K
Relative Volume:
0.77
Market Cap:
$5.07B
Revenue:
$1.34M
Net Income/Loss:
$-173.66M
P/E Ratio:
-21.92
EPS:
-4.1385
Net Cash Flow:
$-130.49M
1W Performance:
-10.29%
1M Performance:
-17.59%
6M Performance:
+15.48%
1Y Performance:
+143.91%
1-Day Range:
$90.36
$94.95
1-Week Range:
$89.78
$104.55
52-Week Range:
$32.22
$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
90.71 | 5.07B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-10-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering? - Yahoo Finance
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run - Yahoo Finance
Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics (DNTH) Stock Analysis: Exploring a 39% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares - Stock Titan
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.03 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at JPMorgan Chase & Co. - MarketBeat
JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating - Yahoo Finance
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com South Africa
DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion - TradingView
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement - Seeking Alpha
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen - Yahoo Finance
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options - Kalkine Media
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug - Seeking Alpha
Citigroup Initiates Dianthus Therapeutics at Buy With $156 Price Target - Yahoo Finance
Dianthus Therapeutics EVP Simrat Randhawa Executes Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics to Participate in Three Investor Conferences During September - The Manila Times
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case - Seeking Alpha
Dianthus (DNTH) Quarterly Figures: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - vinanet.vn
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Director Simon Read Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133 - Moomoo
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock By Investing.com - Investing.com Nigeria
Dianthus therapeutics director Simon Read sells $304k in stock - Investing.com
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock - Investing.com
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):